1. Home
  2. CRSP vs TGS Comparison

CRSP vs TGS Comparison

Compare CRSP & TGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • TGS
  • Stock Information
  • Founded
  • CRSP 2013
  • TGS 1992
  • Country
  • CRSP Switzerland
  • TGS Argentina
  • Employees
  • CRSP N/A
  • TGS 1207
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • TGS Natural Gas Distribution
  • Sector
  • CRSP Health Care
  • TGS Utilities
  • Exchange
  • CRSP Nasdaq
  • TGS Nasdaq
  • Market Cap
  • CRSP 3.3B
  • TGS 4.6B
  • IPO Year
  • CRSP 2016
  • TGS N/A
  • Fundamental
  • Price
  • CRSP $36.29
  • TGS $28.09
  • Analyst Decision
  • CRSP Buy
  • TGS Strong Buy
  • Analyst Count
  • CRSP 16
  • TGS 1
  • Target Price
  • CRSP $73.07
  • TGS $40.00
  • AVG Volume (30 Days)
  • CRSP 2.1M
  • TGS 312.6K
  • Earning Date
  • CRSP 05-06-2025
  • TGS 05-09-2025
  • Dividend Yield
  • CRSP N/A
  • TGS N/A
  • EPS Growth
  • CRSP N/A
  • TGS 247.30
  • EPS
  • CRSP N/A
  • TGS 0.48
  • Revenue
  • CRSP $37,675,000.00
  • TGS $1,159,816,418.00
  • Revenue This Year
  • CRSP $26.79
  • TGS N/A
  • Revenue Next Year
  • CRSP $297.32
  • TGS N/A
  • P/E Ratio
  • CRSP N/A
  • TGS $11.64
  • Revenue Growth
  • CRSP N/A
  • TGS 16.31
  • 52 Week Low
  • CRSP $30.04
  • TGS $14.16
  • 52 Week High
  • CRSP $67.88
  • TGS $34.37
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 46.12
  • TGS 45.69
  • Support Level
  • CRSP $35.38
  • TGS $30.01
  • Resistance Level
  • CRSP $38.13
  • TGS $31.10
  • Average True Range (ATR)
  • CRSP 1.73
  • TGS 1.39
  • MACD
  • CRSP -0.03
  • TGS -0.25
  • Stochastic Oscillator
  • CRSP 26.30
  • TGS 5.98

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About TGS Transportadora de Gas del Sur SA TGS

Transportadora de Gas del Sur SA is a transporters of natural gas in Latin America. The company's operating segments include Natural Gas Transportation, Midstream, Telecommunications, Production and Commercialization Liquids, Other Services, and Telecommunications. It generates maximum revenue from the Production and Commercialization of the Liquids segment. Geographically, it derives the majority of its revenue from Argentina.

Share on Social Networks: